A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase*

Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase required for signaling from immunoreceptors in various hematopoietic cells. Phosphorylation of two tyrosine residues in the activation loop of the Syk kinase catalytic domain is necessary for signaling, a phenomenon typical of tyrosine kinase family members. Syk in vitro enzyme activity, however, does not depend on phosphorylation (activation loop tyrosine → phenylalanine mutants retain catalytic activity). We have determined the x-ray structure of the unphosphorylated form of the kinase catalytic domain of Syk. The enzyme adopts a conformation of the activation loop typically seen only in activated, phosphorylated tyrosine kinases, explaining why Syk does not require phosphorylation for activation. We also demonstrate that Gleevec (STI-571, Imatinib) inhibits the isolated kinase domains of both unphosphorylated Syk and phosphorylated Abl with comparable potency. Gleevec binds Syk in a novel, compact cis-conformation that differs dramatically from the binding mode observed with unphosphorylated Abl, the more Gleevec-sensitive form of Abl. This finding suggests the existence of two distinct Gleevec binding modes: an extended, trans-conformation characteristic of tight binding to the inactive conformation of a protein kinase and a second compact, cis-conformation characteristic of weaker binding to the active conformation. Finally, the Syk-bound cis-conformation of Gleevec bears a striking resemblance to the rigid structure of the nonspecific, natural product kinase inhibitor staurosporine.

[1]  Eugene C. Petrella,et al.  The Three-dimensional Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine , 2004, Journal of Biological Chemistry.

[2]  J. D. Di Santo,et al.  Tyrosine kinase SYK: essential functions for immunoreceptor signalling. , 2000, Immunology today.

[3]  S. Hubbard Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[4]  M. Shibuya,et al.  Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Veillette,et al.  Differential Intrinsic Enzymatic Activity of Syk and Zap-70 Protein-tyrosine Kinases* , 1996, The Journal of Biological Chemistry.

[6]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[7]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[8]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[9]  Hsien-yu Wang,et al.  Gsα Repression of Adipogenesis via Syk* , 1999, The Journal of Biological Chemistry.

[10]  L. Johnson,et al.  Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 , 1997, Nature Structural Biology.

[11]  M. Shibuya,et al.  A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. , 1992, Biochemical and biophysical research communications.

[12]  M. Turner,et al.  Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. , 1996, Oncogene.

[13]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[14]  L. Toledo,et al.  Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.

[15]  S. Hubbard,et al.  Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. , 1997, Science.

[16]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[17]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[18]  K. Sada,et al.  Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling , 1995, The Journal of experimental medicine.

[19]  T. Hunter,et al.  The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  Teruaki Kimura,et al.  Mutations in the activation loop tyrosines of protein tyrosine kinase Syk abrogate intracellular signaling but not kinase activity. , 1998, Journal of immunology.

[21]  S. Hubbard,et al.  Protein tyrosine kinase structure and function. , 2000, Annual review of biochemistry.

[22]  Jürg Zimmermann,et al.  Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .

[23]  J. Zhang,et al.  Transfection of Syk protein tyrosine kinase reconstitutes high affinity IgE receptor-mediated degranulation in a Syk-negative variant of rat basophilic leukemia RBL-2H3 cells , 1996, The Journal of experimental medicine.

[24]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[25]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[26]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[27]  S. Latour,et al.  Proximal protein tyrosine kinases in immunoreceptor signaling. , 2001, Current opinion in immunology.

[28]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[29]  J. Kuriyan,et al.  Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. , 1999, Molecular cell.

[30]  John Badger,et al.  Reliable quality-control methods for protein crystal structures. , 2002, Acta crystallographica. Section D, Biological crystallography.

[31]  Hiroto Yamaguchi,et al.  Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.

[32]  S. Hubbard,et al.  Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.

[33]  T. Mustelin,et al.  Role of Tyr518 and Tyr519 in the regulation of catalytic activity and substrate phosphorylation by Syk protein-tyrosine kinase. , 1997, European journal of biochemistry.

[34]  W. Hofmann,et al.  Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia , 2004, Leukemia & lymphoma.

[35]  S. Knapp,et al.  Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Weiss,et al.  The Syk family of protein tyrosine kinases in T‐cell activation and development , 1998, Immunological reviews.

[37]  Randall L. Kincaid,et al.  Phosphorylation of Syk Activation Loop Tyrosines Is Essential for Syk Function , 2000, The Journal of Biological Chemistry.